<DOC>
	<DOCNO>NCT02041130</DOCNO>
	<brief_summary>Investigators test new approach form heart failure ( HF ) current treatment proven reduce death rate hospitalisation . Over third HF case preserve ejection fraction ( HFPEF ) often background high blood pressure ( BP ) . These `` stiff '' heart pump strongly fill inefficiently result poor exercise capacity high death rate . Treatments help heart pump action poor benefit HFPEF . Recently simple catheter procedure remove excess nerve signal kidney ( `` renal denervation '' ; RDN ) able reduce BP patient high BP resistant multi-drug treatment . Through remove excess nervous drive kidney , heart circulation treatment promise HF . The investigator compare effect RDN standard medical treatment heart function , exercise capacity quality life 144 patient HFPEF</brief_summary>
	<brief_title>Renal Denervation Heart Failure Patients With Preserved Ejection Fraction ( RESPECT-HF )</brief_title>
	<detailed_description>Rationale Research : - Heart failure ( HF ) common lethal . It common diagnosis medical admission 60 year age , carry &gt; 50 % 5 year mortality account 1-2 % total national health care budget . HF preserve ejection fraction ( HFPEF ) include third HF case present New Zealand Singapore Hospitals treatment proven reduce mortality recurrent admission . Renal denervation ( RDN ) proven efficacy refractory hypertension array effect upon haemodynamic status , neurohumoral activity renal function make rational candidate therapy HFPEF . Aims : - The investigator aim conduct phase 2 randomize control trial RDN HFPEF determine effect upon cardiac structure function , exercise capacity , quality life . Primary Hypothesis : RDN reduce leave atrial volume index ( LAVi ) and/or leave ventricular mass index ( LVMi ) cardiac magnetic resonance imaging ( cMRI ) . Secondary Hypotheses : RDN : 1. improve exercise capacity functional status . 2. reduce E/e ' echocardiographic grade diastolic dysfunction . 3. reduce circulate biomarkers cardiac load , interstitial fibrosis inflammation . 4. improve ventricular-vascular function . 5. improve Minnesota Living Heart Failure ( MLWHF ) score . 6. reduce composite end-point death re-admission HF . Design Methods : - Renal denervation test therapy HFPEF multi-centre open , randomize control trial bilateral renal artery denervation compare ongoing medical management . Sample size ( n=144 ) sufficient provide 90 % power detect clinically relevant effect primary endpoint change leave atrial volume leave ventricular mass 6 month post-RDN . Secondary end-points include assessment exercise capacity , ventricular-vascular coupling , biomarkers ( cardiac haemodynamic load , fibrosis , inflammation cardiomyocyte loss ) , quality life cardiovascular event . Research Impact : - Heart Failure Preserved Ejection Fraction ( HFPEF ) common , trigger recurrent hospital admission high mortality carry high burden health care cost . There currently treatment reduces admissions improves survival condition . If efficacy proven , renal nerve denervation represent simple , cost-effective , one time , approach find rapid uptake potentially thousand cases.If current proposal generates positive result ( followed positive phase 3 trial ) investigator conservatively estimate RDN may reduce mortality HF admission HFPEF least 30 % .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Patients HFPEF ( base upon ESC diagnostic criteria9 ) 1 . Symptoms sign heart failure ; NYHA Class II high 2 . Left ventricular ejection fraction 50 % great echocardiography 3 . Echocardiographic evidence leave ventricular diastolic dysfunction ( echoDoppler E/e ' &gt; 15 ) AND/OR plasma NTproBNP &gt; 220pg/ml . 2 . Episode acute decompensation ( ADHF ) 3 . Patients without background hypertension may recruit . In case patient background hypertension ( ie history fulfil diagnostic WHO criteria hypertension : SBP &gt; 140 mmHg and/or DBP &gt; 90 mmHg ) control ( &lt; 140/90mmHg 24 hour ambulatory BP ) inadequately control BP ( 3 antihypertensive drug include diuretic ) recruit . 1 . Known secondary cause hypertension 2 . Renal artery stenosis &gt; 30 % anatomy otherwise unsuitable RDN . 3 . Heart failure reduce LV ejection fraction ( LVEF &lt; 50 % ) . 4 . Estimated glomerular filtration rate ( eGFR ) &lt; 30mL/min/1.73m2 ( MDRD calculation ) . 5 . Systolic blood pressure &lt; 105mmHg . 6 . Implanted pacemaker , prosthetic heart valve preclude cMR scanning . 7 . Medical condition adversely affect safety and/or effectiveness participant ( include peripheral vascular disease , abdominal aortic aneurysm , thrombocytopenia atrial fibrillation ) . 8 . Pregnant , nurse planning pregnant . 9 . Uncontrolled atrial fibrillation , ie heart rate 120 bpm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Heart Failure Preserved Ejection Fraction</keyword>
</DOC>